Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 5712 entries
Sorted by: Best Match Show Resources per page
Identifying Consistent Inconsistency in Network Meta-Analyses - An Illustration In Type 2 Diabetes.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Hawkins N, Scott DA.
PMID: 27200589
Value Health. 2014 Nov;17(7):A334. doi: 10.1016/j.jval.2014.08.638. Epub 2014 Oct 26.

No abstract available.

Cite
Hawkins N, Scott DA. Identifying Consistent Inconsistency in Network Meta-Analyses - An Illustration In Type 2 Diabetes. Value Health. 2014;17(7):A334doi: 10.1016/j.jval.2014.08.638.
Hawkins, N., & Scott, D. A. (2014). Identifying Consistent Inconsistency in Network Meta-Analyses - An Illustration In Type 2 Diabetes. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A334. https://doi.org/10.1016/j.jval.2014.08.638
Hawkins, N, and Scott, D A. "Identifying Consistent Inconsistency in Network Meta-Analyses - An Illustration In Type 2 Diabetes." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A334. doi: https://doi.org/10.1016/j.jval.2014.08.638
Hawkins N, Scott DA. Identifying Consistent Inconsistency in Network Meta-Analyses - An Illustration In Type 2 Diabetes. Value Health. 2014 Nov;17(7):A334. doi: 10.1016/j.jval.2014.08.638. Epub 2014 Oct 26. PMID: 27200589.
Copy Download .nbib Format: NLM
The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Diels J, Angermund R, Schroeder M, Worbes-Cerezo M, Thompson G.
PMID: 27200590
Value Health. 2014 Nov;17(7):A334. doi: 10.1016/j.jval.2014.08.639. Epub 2014 Oct 26.

No abstract available.

Cite
Diels J, Angermund R, Schroeder M, et al. The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM). Value Health. 2014;17(7):A334doi: 10.1016/j.jval.2014.08.639.
Diels, J., Angermund, R., Schroeder, M., Worbes-Cerezo, M., & Thompson, G. (2014). The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A334. https://doi.org/10.1016/j.jval.2014.08.639
Diels, J, et al. "The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A334. doi: https://doi.org/10.1016/j.jval.2014.08.639
Diels J, Angermund R, Schroeder M, Worbes-Cerezo M, Thompson G. The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM). Value Health. 2014 Nov;17(7):A334. doi: 10.1016/j.jval.2014.08.639. Epub 2014 Oct 26. PMID: 27200590.
Copy Download .nbib Format: NLM
Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Hawkins N, Padhiar A, Thompson J, Scott DA, Eaton JN, Varol N, Norrbacka K, Boye KS, Nicolay C.
PMID: 27200592
Value Health. 2014 Nov;17(7):A335. doi: 10.1016/j.jval.2014.08.641. Epub 2014 Oct 26.

No abstract available.

Cite
Hawkins N, Padhiar A, Thompson J, et al. Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes. Value Health. 2014;17(7):A335doi: 10.1016/j.jval.2014.08.641.
Hawkins, N., Padhiar, A., Thompson, J., Scott, D. A., Eaton, J. N., Varol, N., Norrbacka, K., Boye, K. S., & Nicolay, C. (2014). Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A335. https://doi.org/10.1016/j.jval.2014.08.641
Hawkins, N, et al. "Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A335. doi: https://doi.org/10.1016/j.jval.2014.08.641
Hawkins N, Padhiar A, Thompson J, Scott DA, Eaton JN, Varol N, Norrbacka K, Boye KS, Nicolay C. Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes. Value Health. 2014 Nov;17(7):A335. doi: 10.1016/j.jval.2014.08.641. Epub 2014 Oct 26. PMID: 27200592.
Copy Download .nbib Format: NLM
Recombinant Growth Hormone Therapy in Children with GH Deficiency: First Interventional Study in Armenia.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Markosyan R, Perikhanyan A.
PMID: 27200601
Value Health. 2014 Nov;17(7):A336. doi: 10.1016/j.jval.2014.08.646. Epub 2014 Oct 26.

No abstract available.

Cite
Markosyan R, Perikhanyan A. Recombinant Growth Hormone Therapy in Children with GH Deficiency: First Interventional Study in Armenia. Value Health. 2014;17(7):A336doi: 10.1016/j.jval.2014.08.646.
Markosyan, R., & Perikhanyan, A. (2014). Recombinant Growth Hormone Therapy in Children with GH Deficiency: First Interventional Study in Armenia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A336. https://doi.org/10.1016/j.jval.2014.08.646
Markosyan, R, and Perikhanyan, A. "Recombinant Growth Hormone Therapy in Children with GH Deficiency: First Interventional Study in Armenia." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A336. doi: https://doi.org/10.1016/j.jval.2014.08.646
Markosyan R, Perikhanyan A. Recombinant Growth Hormone Therapy in Children with GH Deficiency: First Interventional Study in Armenia. Value Health. 2014 Nov;17(7):A336. doi: 10.1016/j.jval.2014.08.646. Epub 2014 Oct 26. PMID: 27200601.
Copy Download .nbib Format: NLM
Effectiveness, Safety and Patients' Subjective Feelings of Insulin Pen-Needle: A Systematic Review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Sun L, Sun J, Chen B, Sun S, Wang R, Ren X.
PMID: 27200602
Value Health. 2014 Nov;17(7):A336. doi: 10.1016/j.jval.2014.08.647. Epub 2014 Oct 26.

No abstract available.

Cite
Sun L, Sun J, Chen B, et al. Effectiveness, Safety and Patients' Subjective Feelings of Insulin Pen-Needle: A Systematic Review. Value Health. 2014;17(7):A336doi: 10.1016/j.jval.2014.08.647.
Sun, L., Sun, J., Chen, B., Sun, S., Wang, R., & Ren, X. (2014). Effectiveness, Safety and Patients' Subjective Feelings of Insulin Pen-Needle: A Systematic Review. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A336. https://doi.org/10.1016/j.jval.2014.08.647
Sun, L, et al. "Effectiveness, Safety and Patients' Subjective Feelings of Insulin Pen-Needle: A Systematic Review." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A336. doi: https://doi.org/10.1016/j.jval.2014.08.647
Sun L, Sun J, Chen B, Sun S, Wang R, Ren X. Effectiveness, Safety and Patients' Subjective Feelings of Insulin Pen-Needle: A Systematic Review. Value Health. 2014 Nov;17(7):A336. doi: 10.1016/j.jval.2014.08.647. Epub 2014 Oct 26. PMID: 27200602.
Copy Download .nbib Format: NLM
Estimation of Costs Associated With Stroke In Diabetic Patients in Madrid (Spain) Using A New Simulation Model.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Sánchez-Piedra C, García-Pérez S, Sarría-Santamera A.
PMID: 27200615
Value Health. 2014 Nov;17(7):A339. doi: 10.1016/j.jval.2014.08.666. Epub 2014 Oct 26.

No abstract available.

Cite
Sánchez-Piedra C, García-Pérez S, Sarría-Santamera A. Estimation of Costs Associated With Stroke In Diabetic Patients in Madrid (Spain) Using A New Simulation Model. Value Health. 2014;17(7):A339doi: 10.1016/j.jval.2014.08.666.
Sánchez-Piedra, C., García-Pérez, S., & Sarría-Santamera, A. (2014). Estimation of Costs Associated With Stroke In Diabetic Patients in Madrid (Spain) Using A New Simulation Model. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A339. https://doi.org/10.1016/j.jval.2014.08.666
Sánchez-Piedra, C, et al. "Estimation of Costs Associated With Stroke In Diabetic Patients in Madrid (Spain) Using A New Simulation Model." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A339. doi: https://doi.org/10.1016/j.jval.2014.08.666
Sánchez-Piedra C, García-Pérez S, Sarría-Santamera A. Estimation of Costs Associated With Stroke In Diabetic Patients in Madrid (Spain) Using A New Simulation Model. Value Health. 2014 Nov;17(7):A339. doi: 10.1016/j.jval.2014.08.666. Epub 2014 Oct 26. PMID: 27200615.
Copy Download .nbib Format: NLM
Estimation of Costs Associated With Cardiovascular Complications of Diabetic Patients In Madrid (Spain) Using A New Simulation Model.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

García-Pérez S, Sánchez-Piedra C, Sarría-Santamera A.
PMID: 27200616
Value Health. 2014 Nov;17(7):A339. doi: 10.1016/j.jval.2014.08.667. Epub 2014 Oct 26.

No abstract available.

Cite
García-Pérez S, Sánchez-Piedra C, Sarría-Santamera A. Estimation of Costs Associated With Cardiovascular Complications of Diabetic Patients In Madrid (Spain) Using A New Simulation Model. Value Health. 2014;17(7):A339doi: 10.1016/j.jval.2014.08.667.
García-Pérez, S., Sánchez-Piedra, C., & Sarría-Santamera, A. (2014). Estimation of Costs Associated With Cardiovascular Complications of Diabetic Patients In Madrid (Spain) Using A New Simulation Model. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A339. https://doi.org/10.1016/j.jval.2014.08.667
García-Pérez, S, et al. "Estimation of Costs Associated With Cardiovascular Complications of Diabetic Patients In Madrid (Spain) Using A New Simulation Model." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A339. doi: https://doi.org/10.1016/j.jval.2014.08.667
García-Pérez S, Sánchez-Piedra C, Sarría-Santamera A. Estimation of Costs Associated With Cardiovascular Complications of Diabetic Patients In Madrid (Spain) Using A New Simulation Model. Value Health. 2014 Nov;17(7):A339. doi: 10.1016/j.jval.2014.08.667. Epub 2014 Oct 26. PMID: 27200616.
Copy Download .nbib Format: NLM
ARE TOTAL HEALTH CARE EXPENDITURES IMPACTED BY A NEW DIABETES DIAGNOSTIC FACTOR: HBA1C?.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Bhounsule P, Peterson AM.
PMID: 27200617
Value Health. 2014 Nov;17(7):A339. doi: 10.1016/j.jval.2014.08.664. Epub 2014 Oct 26.

No abstract available.

Cite
Bhounsule P, Peterson AM. ARE TOTAL HEALTH CARE EXPENDITURES IMPACTED BY A NEW DIABETES DIAGNOSTIC FACTOR: HBA1C?. Value Health. 2014;17(7):A339doi: 10.1016/j.jval.2014.08.664.
Bhounsule, P., & Peterson, A. M. (2014). ARE TOTAL HEALTH CARE EXPENDITURES IMPACTED BY A NEW DIABETES DIAGNOSTIC FACTOR: HBA1C?. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A339. https://doi.org/10.1016/j.jval.2014.08.664
Bhounsule, P, and Peterson, A M. "ARE TOTAL HEALTH CARE EXPENDITURES IMPACTED BY A NEW DIABETES DIAGNOSTIC FACTOR: HBA1C?." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A339. doi: https://doi.org/10.1016/j.jval.2014.08.664
Bhounsule P, Peterson AM. ARE TOTAL HEALTH CARE EXPENDITURES IMPACTED BY A NEW DIABETES DIAGNOSTIC FACTOR: HBA1C?. Value Health. 2014 Nov;17(7):A339. doi: 10.1016/j.jval.2014.08.664. Epub 2014 Oct 26. PMID: 27200617.
Copy Download .nbib Format: NLM
Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Kawalec P.
PMID: 27200624
Value Health. 2014 Nov;17(7):A340. doi: 10.1016/j.jval.2014.08.673. Epub 2014 Oct 26.

No abstract available.

Cite
Kawalec P. Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland. Value Health. 2014;17(7):A340doi: 10.1016/j.jval.2014.08.673.
Kawalec, P. (2014). Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A340. https://doi.org/10.1016/j.jval.2014.08.673
Kawalec, P. "Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A340. doi: https://doi.org/10.1016/j.jval.2014.08.673
Kawalec P. Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland. Value Health. 2014 Nov;17(7):A340. doi: 10.1016/j.jval.2014.08.673. Epub 2014 Oct 26. PMID: 27200624.
Copy Download .nbib Format: NLM
Comparison of the Economic Burden and Health care Utilizations of u. S. Veteran Patients Diagnosed with Type 2 Diabetes Mellitus.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Xie L, Kariburyo MF, Wang Y, Baser O.
PMID: 27200626
Value Health. 2014 Nov;17(7):A341. doi: 10.1016/j.jval.2014.08.677. Epub 2014 Oct 26.

No abstract available.

Cite
Xie L, Kariburyo MF, Wang Y, et al. Comparison of the Economic Burden and Health care Utilizations of u. S. Veteran Patients Diagnosed with Type 2 Diabetes Mellitus. Value Health. 2014;17(7):A341doi: 10.1016/j.jval.2014.08.677.
Xie, L., Kariburyo, M. F., Wang, Y., & Baser, O. (2014). Comparison of the Economic Burden and Health care Utilizations of u. S. Veteran Patients Diagnosed with Type 2 Diabetes Mellitus. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A341. https://doi.org/10.1016/j.jval.2014.08.677
Xie, L, et al. "Comparison of the Economic Burden and Health care Utilizations of u. S. Veteran Patients Diagnosed with Type 2 Diabetes Mellitus." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A341. doi: https://doi.org/10.1016/j.jval.2014.08.677
Xie L, Kariburyo MF, Wang Y, Baser O. Comparison of the Economic Burden and Health care Utilizations of u. S. Veteran Patients Diagnosed with Type 2 Diabetes Mellitus. Value Health. 2014 Nov;17(7):A341. doi: 10.1016/j.jval.2014.08.677. Epub 2014 Oct 26. PMID: 27200626.
Copy Download .nbib Format: NLM
Medical Expenditures Associated With Type 2 Diabetes Mellitus in Japan: A Large Claims Database Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Fukuda H, Ikeda S, Shiroiwa T, Igarashi A, Fukuda T.
PMID: 27200628
Value Health. 2014 Nov;17(7):A341. doi: 10.1016/j.jval.2014.08.678. Epub 2014 Oct 26.

No abstract available.

Cite
Fukuda H, Ikeda S, Shiroiwa T, et al. Medical Expenditures Associated With Type 2 Diabetes Mellitus in Japan: A Large Claims Database Study. Value Health. 2014;17(7):A341doi: 10.1016/j.jval.2014.08.678.
Fukuda, H., Ikeda, S., Shiroiwa, T., Igarashi, A., & Fukuda, T. (2014). Medical Expenditures Associated With Type 2 Diabetes Mellitus in Japan: A Large Claims Database Study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A341. https://doi.org/10.1016/j.jval.2014.08.678
Fukuda, H, et al. "Medical Expenditures Associated With Type 2 Diabetes Mellitus in Japan: A Large Claims Database Study." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A341. doi: https://doi.org/10.1016/j.jval.2014.08.678
Fukuda H, Ikeda S, Shiroiwa T, Igarashi A, Fukuda T. Medical Expenditures Associated With Type 2 Diabetes Mellitus in Japan: A Large Claims Database Study. Value Health. 2014 Nov;17(7):A341. doi: 10.1016/j.jval.2014.08.678. Epub 2014 Oct 26. PMID: 27200628.
Copy Download .nbib Format: NLM
Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Troelsgaard A, Pitcher A, Veselá Š, Lovato E, Hemels M.
PMID: 27200633
Value Health. 2014 Nov;17(7):A342-3. doi: 10.1016/j.jval.2014.08.685. Epub 2014 Oct 26.

No abstract available.

Cite
Troelsgaard A, Pitcher A, Veselá Š, et al. Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic. Value Health. 2014;17(7):A342-3doi: 10.1016/j.jval.2014.08.685.
Troelsgaard, A., Pitcher, A., Veselá, �. �., Lovato, E., & Hemels, M. (2014). Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A342-3. https://doi.org/10.1016/j.jval.2014.08.685
Troelsgaard, A, et al. "Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A342-3. doi: https://doi.org/10.1016/j.jval.2014.08.685
Troelsgaard A, Pitcher A, Veselá Š, Lovato E, Hemels M. Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic. Value Health. 2014 Nov;17(7):A342-3. doi: 10.1016/j.jval.2014.08.685. Epub 2014 Oct 26. PMID: 27200633.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 5712 entries